respiratory
PROMISE Score for Malignant Pleural Effusion Prognosis
Prognostic score for patients with malignant pleural effusion (MPE). Predicts 3-month mortality. Based on LENT score variables plus Performance status. Score 0-7: score 0-1 = low risk (median survival above 12 months); 2-4 = intermediate; 5-7 = high risk (median survival 2 months). Helps guide intervention choices (indwelling pleural catheter vs talc pleurodesis). From Bibby et al. 2018.
References
- Bibby AC et al. The PROMISE grading system: a new tool for assessing clinical outcomes and survival in malignant pleural mesothelioma. BMJ Open. 2018;8(9):e021341.
- Roberts ME et al. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2023. Thorax. 2023;78(Suppl 3):s19-s44.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Hydroxycarbamide (Hydroxyurea) · Cytotoxic / Disease-Modifying Agent
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.